Regeneron's Eylea Beats Roche's Lucentis in New Head-to-head Study
Saturday, February 21, 2015
Source: Fierce Medical
Regeneron's ($REGN) eye drug Eylea picked up steam against two competing products from Roche ($RHHBY), as the first head-to-head study comparing the meds found that Eylea outperformed Lucentis and Avastin in treating moderate to severe vision loss in patients with diabetic macular edema (DME).
Eylea bested Roche's drugs in patients with eyesight equal to or worse than 20/50, but Avastin and Lucentis performed similarly to Regeneron's drug in patients with 20/40 vision or better. Individuals with 20/50 vision or worse scored an average visual-acuity letter score improvement of 18.9 when treated with Eylea, compared to 14.2 for patients treated with Lucentis and 11.8 for individuals taking Avastin, according to the results. The study, which was sponsored by the U.S. National Institutes of Health, included 660 participants and was published on Thursday in the New England Journal of Medicine. That is equal to being able to read at least one line of smaller print on an eye chart, the study said.